International Journal of Biomedicine. 2022;12(3):466-469.
Originally published September 5, 2022
The aim of the study was a comparative analysis of the blood value of the leukocyte shift index (LSI) in acute suppurative otitis media (ASOM) and chronic suppurative otitis media (CSOM), depending on the age of children.
Methods and Results: This study included 100 children (62 boys and 38 girls) aged 1-16 years who were diagnosed with ASOM and CSOM. The mean age of all patients was 7.59±0.50 years. Group 1 included 50 patients (30 boys and 20 girls) with ASOM. Group 2 included 50 patients (20 boys and 30 girls) with CSOM. As a marker for determining the activity of the inflammatory process, we chose LSI, calculated taking into account the parameters of the general blood test. LSI levels in the patients of Group 1 and Group 2 were 2.08±0.23 and 1.51±0.16, respectively (P=0.0446). The results obtained indicate that in children with mean age of 3.44±0.31 years, the LSI level of 2.08±0.23 can suggest the formation of ASOM. In children with mean age of 11.56±0.46 years, the LSI level of 1.51±0.16 can suggest the formation of CSOM.
Conclusion: The proposed method for predicting CSOM in children has enough grounds for clinical application in practical health care.
- Garashchenko TI, Kozlova RS. [Acute otitis media in children. Prejudices of pharmacotherapy[. Detskaya Otorinolaringologiya. 2013;(3):31-36. [Article in Russian].
- Stangerup SE, Drozdziewicz D, Tos M, Trabalzini F. Surgery for acquired cholesteatoma in children: long-term results and recurrence of cholesteatoma. J Laryngol Otol. 1998 Aug;112(8):742-9. doi: 10.1017/s0022215100141581.
- Vlasova GV, Kuryanova YuA. [Middle ear cholesteatoma in children: features of the course and results of surgical treatment in the age aspect]. Pediatrics. 2017;8(S): М89-М90. [Article in Russian].
- Vlasova GV. Age aspects of the clinical course of the middle ear cholesteatoma in children. Bulletin of Otorhinolaryngology. 2020:85(1):25-29. [Article in Russian].
- Mallet Y, Nouwen J, Lecomte-Houcke M, Desaulty A. Aggressiveness and quantification of epithelial proliferation of middle ear cholesteatoma by MIB1. Laryngoscope. 2003 Feb;113(2):328-31. doi: 10.1097/00005537-200302000-00024.
- Drahy A, De Barros A, Lerosey Y, Choussy O, Dehesdin D, Marie JP. Acquired cholesteatoma in children: strategies and medium-term results. Eur Ann Otorhinolaryngol Head Neck Dis. 2012 Oct;129(5):225-9. doi: 10.1016/j.anorl.2011.10.011.
- Vartiainen E. Factors associated with recurrence of cholesteatoma. J Laryngol Otol. 1995 Jul;109(7):590-2. doi: 10.1017/s0022215100130804.
- Sadé J, Fuchs C. Cholesteatoma: ossicular destruction in adults and children. J Laryngol Otol. 1994 Jul;108(7):541-4. doi: 10.1017/s0022215100127380.
- Vlasova GV, Pavlova P. [Clinical observation of patient with systemic inflammatory reaction following chronic suppurative otitis media]. Pediatriya - Zhurnal im G.N. Speranskogo. 2015;94(6):182-185. [Article in Russian].
- Kuznetsova NE, Sinyakov AYu, Veshkurtseva IM, et al. The nature of intracranial complications in purulent-inflammatory ear pathology in children. "Mir Nauki", 2019. [In Russian].
- Krivopalov A, Yanov YuK, Shcherbuk AYu, et al. [Oto- and rhinosinusogenic purulent-inflammatory intracranial complications in children]. Proceedings of the XIX Congress of Otorhinolaryngologists of Russia. Moscow; 2016:120-121. [Article in Russian].
- Ivanov DO, Shabalov NP, Shabalova NN, Kurzina EA, Kostyuchek IN. [Leukocyte indices of cellular reactivity as an indicator of the presence of hypo- and hyperergic variants of neonatal sepsis]. Available from: http://www.medlinks.ru/article.php?sid=22330.[Article in Russian].
- Speransky II, Samoilenko GE, Lobacheva MV. [Complete blood count - are all of its possibilities exhausted? Integral indices of intoxication as criteria for assessing the severity of endogenous intoxication, its complications, and the effectiveness of treatment]. Acute and Emergency Conditions in the Practice of a Doctor. 2009.19(6):5. [Article in Russian].
Received June 1, 2022.
Accepted July 7, 2022.
©2022 International Medical Research and Development Corporation.